Hypercortisolism Toolkit

Click here to take the survey and receive your certificate.

Download a PDF of the deck, "Difficult-to-Control Diabetes: Consider Hypercortisolism" (PDF will download to your computer or open in new window, depending on your browser settings)

References

1. Reincke M, Fleseriu M. Cushing Syndrome: A Review. JAMA. 2023;330(2):170. doi:10.1001/jama.2023.11305

   https://pubmed.ncbi.nlm.nih.gov/37432427/

2. Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526- 1540. doi:10.1210/jc.2008-0125

   https://pubmed.ncbi.nlm.nih.gov/18334580/

3. Kelsall A, Newell-Price J. Cushing’s disease-from Minnie G to key issues in the early 21st century. Lancet Diabetes Endocrinol. 2019;7(12):959-964. doi:10.1016/S2213- 8587(19)30343-2

   https://pubmed.ncbi.nlm.nih.gov/31601475/

4. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004;25(2):309-340. doi:10.1210/er.2002-0031

   https://pubmed.ncbi.nlm.nih.gov/15082524/

5. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637-644. doi:10.1210/jcem.85.2.6372

   https://pubmed.ncbi.nlm.nih.gov/10690869/

6. Steffensen C, Dekkers OM, Lyhne J, et al. Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients. Horm Metab Res. 2019;51(1):62-68. doi:10.1055/a-0809-3647

   https://pubmed.ncbi.nlm.nih.gov/30522146/

7. Scoffings K, Morris D, Pullen A, Temple S, Trigell A, Gurnell M. Recognising and diagnosing Cushing’s syndrome in primary care: challenging but not impossible. Br J Gen Pract. 2022;72(721):399-401. doi:10.3399/bjgp22X720449

   https://pubmed.ncbi.nlm.nih.gov/35902256/

8. Braun LT, Vogel F, Zopp S, et al. Whom Should We Screen for Cushing Syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited. The Journal of Clinical Endocrinology & Metabolism. 2022;107(9):e3723-e3730. doi:10.1210/clinem/dgac379

   https://pubmed.ncbi.nlm.nih.gov/35730067/

9. Sharma ST, Nieman LK, Feelders RA. Comorbidities in Cushing’s disease. Pituitary. 2015;18(2):188-194. doi:10.1007/s11102-015-0645-6

   https://pubmed.ncbi.nlm.nih.gov/25724314/

10. Raff H, Sharma ST, Nieman LK. Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing’s syndrome, adrenal insufficiency, and congenital adrenal hyperplasia. Compr Physiol. 2014;4(2):739-769. doi:10.1002/cphy.c130035

    https://pubmed.ncbi.nlm.nih.gov/24715566/

11. Cruz-Topete D, Oakley RH, Cidlowski JA. Glucocorticoid Signaling and the Aging Heart. Front Endocrinol. 2020;11:347. doi:10.3389/fendo.2020.00347

    https://pubmed.ncbi.nlm.nih.gov/32528419/

12. DeFronzo RA, Auchus RJ, Bancos I, et al. Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ Open. 2024;14(7):e081121. doi:10.1136/bmjopen-2023-081121

    https://pubmed.ncbi.nlm.nih.gov/39013654/

13. Yorke E, Atiase Y, Akpalu J, Sarfo-Kantanka O. Screening for Cushing Syndrome at the Primary Care Level: What Every General Practitioner Must Know. International Journal of Endocrinology. 2017;2017:1-6. doi:10.1155/2017/1547358

    https://pubmed.ncbi.nlm.nih.gov/28819359/

14. Fallo F, Di Dalmazi G, Beuschlein F, et al. Diagnosis and management of hypertension in patients with Cushing’s syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension. 2022;40(11):2085-2101. doi:10.1097/HJH.0000000000003252

    https://pubmed.ncbi.nlm.nih.gov/35950979/

15. Valassi E, Chiodini I, Feelders RA, et al. Unmet needs in Cushing’s syndrome: the patients’ perspective. Endocr Connect. 2022;11(7):e220027. doi:10.1530/EC-22-0027

    https://pubmed.ncbi.nlm.nih.gov/35904235/

16. Page-Wilson G, Oak B, Silber A, et al. Evaluating the burden of endogenous Cushing’s syndrome using a web-based questionnaire and validated patient-reported outcome measures. Pituitary. 2023;26(4):364-374. doi:10.1007/s11102-023-01314-7

    https://pubmed.ncbi.nlm.nih.gov/37074630/

17. Limumpornpetch P, Morgan AW, Tiganescu A, et al. The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality. The Journal of Clinical Endocrinology & Metabolism. 2022;107(8):2377-2388. doi:10.1210/clinem/dgac265

    https://pubmed.ncbi.nlm.nih.gov/35486378/

18. Lindholm J, Juul S, Jørgensen JOL, et al. Incidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study 1 . The Journal of Clinical Endocrinology & Metabolism. 2001;86(1):117-123. doi:10.1210/jcem.86.1.7093

    https://pubmed.ncbi.nlm.nih.gov/11231987/

19. Dekkers OM, Horváth-Puhó E, Jørgensen JOL, et al. Multisystem Morbidity and Mortality in Cushing’s Syndrome: A Cohort Study. The Journal of Clinical Endocrinology & Metabolism. 2013;98(6):2277-2284. doi:10.1210/jc.2012-3582

    https://pubmed.ncbi.nlm.nih.gov/23533241/

20. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and Morbidity in Cushing’s Disease over 50 Years in Stoke-on-Trent, UK: Audit and Meta-Analysis of Literature. The Journal of Clinical Endocrinology & Metabolism. 2011;96(3):632-642. doi:10.1210/jc.2010- 1942

    https://pubmed.ncbi.nlm.nih.gov/21193542/

21. Araujo-Castro M, Pascual-Corrales E, Lamas C. Possible, probable, and certain hypercortisolism: A continuum in the risk of comorbidity. Annales d’Endocrinologie. 2023;84(2):272-284. doi:10.1016/j.ando.2023.01.005

    https://pubmed.ncbi.nlm.nih.gov/36736771/

22. Costa DS, Conceição FL, Leite NC, Ferreira MT, Salles GF, Cardoso CRL. Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study. J Diabetes Complications. 2016;30(6):1032-1038. doi:10.1016/j.jdiacomp.2016.05.006

    https://pubmed.ncbi.nlm.nih.gov/27210052/

23. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology. 2023;189(1):G1-G42. doi:10.1093/ejendo/lvad066

    https://pubmed.ncbi.nlm.nih.gov/37318239/

24. Chiodini I, Mascia ML, Muscarella S, et al. Subclinical Hypercortisolism among Outpatients Referred for Osteoporosis. Ann Intern Med. 2007;147(8):541. doi:10.7326/0003-4819-147- 8-200710160-00006

    https://pubmed.ncbi.nlm.nih.gov/17938392/

25. Trifanescu R, Carsote M, Caragheorgheopol A, et al. Screening for secondary endocrine hypertension in young patients. Maedica (Bucur). 2013;8(2):108-115.

    https://pubmed.ncbi.nlm.nih.gov/24371473/

26. Martins LC, Conceição FL, Muxfeldt ES, Salles GF. Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension. Journal of Hypertension. 2012;30(5):967-973. doi:10.1097/HJH.0b013e3283521484

    https://pubmed.ncbi.nlm.nih.gov/22406465/

27. Chiodini I, Torlontano M, Scillitani A, et al. Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur J Endocrinol. 2005;153(6):837-844. doi:10.1530/eje.1.02045

    https://pubmed.ncbi.nlm.nih.gov/16322389/

28. León-Justel A, Madrazo-Atutxa A, Alvarez-Rios AI, et al. A Probabilistic Model for Cushing’s Syndrome Screening in At-Risk Populations: A Prospective Multicenter Study. The Journal of Clinical Endocrinology & Metabolism. 2016;101(10):3747-3754. doi:10.1210/jc.2016-1673

    https://pubmed.ncbi.nlm.nih.gov/27490917/

29. Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003;88(12):5808-5813. doi:10.1210/jc.2003-030254

    https://pubmed.ncbi.nlm.nih.gov/14671173/

30. Van Hulsteijn LT, Pasquali R, Casanueva F, et al. Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis. European Journal of Endocrinology. 2020;182(1):11-21. doi:10.1530/EJE-19-0666

    https://pubmed.ncbi.nlm.nih.gov/31652416/

31. Galm BP, Qiao N, Klibanski A, Biller BMK, Tritos NA. Accuracy of Laboratory Tests for the Diagnosis of Cushing Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2020;105(6):2081-2094. doi:10.1210/clinem/dgaa105

    https://pubmed.ncbi.nlm.nih.gov/32133504/